KYTRIL
LOE ApproachingNDAORALSOLUTION
Approved
Jun 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYTRIL (granisetron) is an oral small-molecule antiemetic approved in 2001 for chemotherapy-induced nausea and vomiting (CINV). It works as a selective 5-HT3 receptor antagonist to block serotonin-mediated emetic signals. The product is now in late-stage lifecycle with loss of exclusivity approaching.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), this brand team is likely consolidating portfolios and shifting focus to retained assets or new launches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Started Apr 2007
171 enrolled
Post-Operative Nausea and Vomiting
Career Relevance
Zero linked job openings signal this is a mature, cost-managed asset with minimal hiring. Working on KYTRIL offers experience in late-lifecycle portfolio management, generic transition, and specialty care sales—valuable for career pivot toward LOE strategy or biosimilar/generic oncology roles.
Brand Manager
Worked on KYTRIL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.